Ionis Pharmaceuticals Inc IONS
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 19, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
16 paragraphs in Risk Factors of the 10-K filed Feb 26, 2026 with nothing like them in the 10-K filed Feb 19, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
● cost and effectiveness of our medicines compared to other available therapies;
Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional inquiries, legislation and executive orders designed to, among other things, reduce drug prices, increase competition (including by enhancing support for generic and biosimilar drugs), lower out-of-pocket drug costs for patients, curtail spread pricing practices by pharmacy benefit managers, and foster scientific innovation to promote better health care and improved health. For example, the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the U.S. pharmaceutical industry. Since its enactment, there have been amendments and judicial, Congressional and executive branch challenges to certain aspects of the Affordable Care Act, as well as efforts to repeal or replace certain aspects of the Affordable Care Act. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand or revenue for our commercial medicines and our medicines in development.
In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs. The IRA, among other things, (1) directed HHS to negotiate the price of certain single-source drugs and biologics that have been on the market for at least seven years covered under Medicare, or the Medicare Drug Price Negotiation Program, and (2) imposed rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. Each year, up to 20 products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.
The current U.S. Presidential administration is pursuing policies to reduce regulations and expenditures across government agencies, including at HHS, the FDA, CMS, and other related agencies, with a particular focus on most favored nation pricing equal to or lower than those paid in other developed nations. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose additional policy changes that create uncertainty for our business. For example, in furtherance of the administration’s drug pricing initiatives, in December 2025, CMS issued proposed rules that, if finalized, would implement new mandatory and voluntary payment models to implement a most favored nation rebate model. These models are referred to as the GLOBE Model, GUARD Model and GENEROUS Model. At this time, it remains unclear whether the proposed models will be finalized and, if so, whether any changes will be made prior to their implementation. These and other recent actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers’ global pricing strategies and profitability, while increasing their operational costs and compliance risks.
● TRYNGOLZA faces competition in FCS from a commercial competitor and, if approved for sHTG, could face competition from commercial competitors in the future;
● DAWNZERA faces competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
● WAINUA faces competition in ATTRv-PN from numerous competitors, including an oral product, and, if approved for ATTR-CM, would face competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
● QALSODY could face competition from a commercial competitor in the future; and
● Obudanersen, if approved, could face competition from commercial competitors in the future, including oral products.
For details regarding medicines that compete or may compete directly with our marketed medicines and late-stage medicines, refer to the section titled, Competition, in Part I, Item 1, Business.
For example, while we continue to activate sites in the U.S., Canada, U.K., Australia and Japan, we revised and resubmitted the study protocol for the REVEAL study of obudanersen to address changes requested by EU regulators and plan to initiate EU sites for this study in 2026. Importantly, we believe we are on track to complete enrollment for this study in 2026.
Show the other 3
In addition, our development and commercialization activities could be harmed or delayed by staffing shortages or a shutdown or other significant disruption of the U.S. government, including the FDA or the U.S. PTO.
We use artificial intelligence in certain aspects of our business, and challenges with properly managing its use could adversely affect our business.
We incorporate artificial intelligence, or AI, solutions into certain aspects of our business, and applications of AI may become important in our operations over time. Our competitors or other third parties may incorporate AI into their businesses more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations.
There are also significant risks involved in developing and deploying AI, and there can be no assurance that the usage of AI will enhance our medicines or the discovery or development of our product candidates or be beneficial to our business, including our efficiency or profitability. It is also uncertain how various laws will apply to content generated by AI. Various governmental authorities have proposed or enacted laws governing the development and use of AI technologies. We are subject to the risks of new or enhanced governmental or regulatory scrutiny, litigation, or other legal liability, ethical concerns, negative consumer perceptions as to automation and AI, or other complications that could adversely affect our business, reputation, or financial results.
● U.S. restrictions on the use of certain foreign biotech equipment and service providers, such as those set forth in the BIOSECURE Act;
Paragraphs in the 10-Q filed Nov 9, 2026 that were not in the one before
New in the latest 10-Q
19 paragraphs in the 10-Q filed Nov 9, 2026 with nothing like them in the 10-Q filed Jul 29, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
Work in process inventory increased as of September 30, 2026 compared to December 31, 2025 primarily due to our purchases of TRYNGOLZA drug substance.
Read in the 10-Q
In June 2026, we exercised our right to opt-out of the shared responsibility and costs for development and U.S. commercialization activities under the agreement. The opt-out became effective on August 1, 2026. Effective August 1, 2026, AstraZeneca is responsible for 100 percent of WAINUA costs under this agreement. We concluded that the development activities we perform and related cost reimbursements we receive from AstraZeneca after the opt-out are within the scope of ASC 606 because we determined AstraZeneca is our customer for the remaining R&D services performance obligation under this collaboration. As a result, we are recognizing cost funding from AstraZeneca related to development expenses incurred after the opt-out as collaborative agreement revenue.
Read in the 10-Q
In connection with the opt-out, certain additional pre-opt-out expenses are reimbursable from AstraZeneca. As of September 30, 2026, these amounts were constrained and no amounts have been recognized in the financial statements.
Read in the 10-Q
We have two collaborations with AstraZeneca: one focused on the development and commercialization of WAINUA and one focused on the treatment of cardiovascular, renal and metabolic diseases. From inception through September 30, 2026, we have received approximately $1.1 billion from these collaborations.
Read in the 10-Q
In October 2026, we achieved a $30 million milestone payment when the FDA approved HIBSAGO for the treatment of CHB infection. We will achieve the next payment of up to $35 million if HIBSAGO is approved in China.
Read in the 10-Q
Show the other 14
In 2017, we initiated a collaboration with Novartis to develop and commercialize pelacarsen. Novartis is responsible for conducting and funding development and regulatory activities for pelacarsen, including a global Phase 3 cardiovascular outcomes study that Novartis initiated in 2019. In September 2026, Novartis announced that the pelacarsen Phase 3 Lp(a)HORIZON study did not meet its primary endpoint of reducing the risk of cardiovascular events compared to placebo. From inception through September 30, 2026, we have received more than $275 million in payments under this collaboration.
Read in the 10-Q
In 2013, we entered into an agreement with Roche to develop treatments for Huntington’s disease, or HD. In the third quarter of 2026, we received a termination notice from Roche for this collaboration that became effective in October 2026.
Read in the 10-Q
From inception through September 30, 2026, we have received more than $ 430 million in payments from our Roche collaborations.
Read in the 10-Q
In September 2026, Novartis announced that the pelacarsen Phase 3 Lp(a)HORIZON study did not meet its primary endpoint of reducing the risk of cardiovascular events compared to placebo. As a result, we no longer expect the FDA approval of pelacarsen and changed our estimate of future pelacarsen royalty payments to zero and total SPINRAZA royalty payments payable to Royalty Pharma from $475 million to $550 million. We accounted for this change in estimate using the prospective interest method by recalculating the effective interest rate based on the carrying amount and the revised estimated future payments to Royalty Pharma as of September 2026. The revised estimated future payments was less than the net carrying amount of our liability. As a result, we began recognizing contra-interest expense over the remaining term of the Royalty Pharma arrangement. This reflects the reversal of previously recognized interest expense that is greater than the updated estimate of total interest expense that we will recognize over the term of the arrangement.
Read in the 10-Q
(1) The current portion represents the estimated reduction in the liability balance over the next twelve months after September 30, 2026, which includes estimated royalty payments to Royalty Pharma and estimated contra-interest expense.
Read in the 10-Q
ZANVASTRO is an RNA-targeted medicine approved in the U.S. for the treatment of AxD in pediatric and adult patients. It is administered intrathecally every three months. ZANVASTRO is the first and only FDA-approved disease modifying treatment for AxD. ZANVASTRO is the third medicine we are commercializing independently in the U.S. We licensed commercialization rights for ZANVASTRO in countries outside of the U.S. to Recordati. ZANVASTRO was granted Orphan Drug designation from the European Medicines Agency, or EMA.
Read in the 10-Q
HIBSAGO (bepirovirsen) is an RNA-targeted medicine approved in the U.S. and Japan for CHB virus infection in adult patients without cirrhosis receiving nucleos(t)ide analogue therapy and with hepatitis B virus, or HBV, surface antigen, or HBsAg, levels ≤3000 IU/ml as determined by an FDA-authorized test. It is a six-month finite treatment that can be administered at-home after the first dose. HIBSAGO offers unprecedented functional cure rates compared to current standard of care. Our partner, GSK, is responsible for commercializing HIBSAGO worldwide.
Read in the 10-Q
Pelacarsen is our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease, or Lp(a)-driven CVD. In September 2026, Novartis announced that the pelacarsen Phase 3 Lp(a)HORIZON study did not meet its primary endpoint of reducing the risk of cardiovascular events compared to placebo. The full Lp(a)HORIZON data will be presented at the American Heart Association, or AHA, conference in November 2026.
Read in the 10-Q
In June 2026, we exercised our right to opt-out of the shared responsibility and costs for development and U.S. commercialization activities under the agreement. The opt-out became effective on August 1, 2026. Effective August 1, 2026, AstraZeneca is responsible for 100 percent of WAINUA costs under this agreement.
Read in the 10-Q
Risk Factors
With respect to TRYNGOLA, it is the first and only treatment approved to reduce triglycerides and the risk of acute pancreatitis in people living with sHTG. As such, we are building a new market that requires health care practitioners to adopt a new approach to patient care, which takes time. Prescribers want to see how a patient responds to treatment with TRYNGOLZA before prescribing more broadly. This dynamic has and may continue to result in a more gradual launch ramp than we originally expected.
Read in the 10-Q
For example, the TRYNGOLZA launch for sHTG is at an early stage where a majority of TRYNGOLZA prescriptions require a medical exemption. Some health care practitioners are hesitant to prescribe a newly approved medicine, like TRYNGOLZA, before formal coverage with payors is in place. We are working with payors to establish coverage for TRYNGOLZA but our success may be limited. In addition, regarding DAWNZERA, we are experiencing increased price pressure from payors in the competitive HAE market.
Read in the 10-Q
Item 6
10.1 Form of Global Restricted Stock Unit Agreement for restricted stock units granted under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
Read in the 10-Q
10.2 Form of Global Option Agreement for stock options granted under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
Read in the 10-Q
10.3 UK Sub-Plan to the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 9, 2026 against Item 1A of the 10-K filed Feb 26, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Show the other 13
The first 18 of 39 are shown (at most 12 of each type).
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 26, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 19, 2025
Where each one is used
- notes due: In 2025, we completed a $770 million offering of 0% Notes due 2030 and used $267.6 million of the net proceeds from the issuance of the 0% Notes due 2030 to repurchase $200 million of our 0% Notes due 2026. In 2023, we completed a $575 million offering of 1.75% Notes due 2028 and used $488.2 million of the net...
- commercial competitors: ● TRYNGOLZA faces competition in FCS from a commercial competitor and, if approved for sHTG, could face competition from commercial competitors in the future;
- set forth: The proximity of our current and planned independent launches could increase the likelihood that the risks set forth above will occur.
- favored nation: The current U.S. Presidential administration is pursuing policies to reduce regulations and expenditures across government agencies, including at HHS, the FDA, CMS, and other related agencies, with a particular focus on most favored nation pricing equal to or lower than those paid in other developed nations. These...
- commercial competitor: ● TRYNGOLZA faces competition in FCS from a commercial competitor and, if approved for sHTG, could face competition from commercial competitors in the future;
- several commercial: ● DAWNZERA faces competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
- additional commercial: ● DAWNZERA faces competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
- details regarding: For details regarding medicines that compete or may compete directly with our marketed medicines and late-stage medicines, refer to the section titled, Competition, in Part I, Item 1, Business.
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
13 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.